PMH61 COMPARISON OF OUTCOMES REPORTED BY INDIVIDUALS WITH SCHIZOPHRENIA RESIDING IN THE COMMUNITY AND OBJECTIVE OUTCOMES REPORTED BY CAREGIVERS  by Barr, J et al.
403Abstracts
antipsychotics, lack of efﬁcacy or tolerability and poor compli-
ance remain frequent reasons for change of therapy.
PMH59
THE ELECTRONIC SCHIZOPHRENIA TREATMENT
ADHERENCE REGISTRY—E-STAR: BASELINE RESULTS FOR
GERMANY, SPAIN AND AUSTRALIA
Rossillon D1, Caleo S2, Farmer D3, Ingham M4, Jacobs A2
1SGS Biopharma, Wavre, Belgium; 2Janssen Pharmaceutica, Beerse,
Belgium; 3Interactive Educational Systems, Ltd, Hampton Court,
Surrey, UK; 4Johnson & Johnson Pharmaceutical Services, Raritan, NJ,
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OBJECTIVES: E-STAR is an ongoing, international, observa-
tional survey evaluating long-term clinical and economic out-
comes in patients switched to a new antipsychotic. METHODS:
Data are collected via a secured web-based system, retrospec-
tively for 12-months and prospectively for two-years. Patient
demographics, treatment and hospitalisation history, reason for
initiating new treatment, Clinical Global Impression—Severity
(CGI-S), Global Assessment of Functioning (GAF) and adverse
event data are collected. RESULTS: Complete baseline and ret-
rospective data are currently available for 1920 patients enrolled:
Germany (n = 744), Spain (n = 709), Australia (n = 467). Patients
reported here switched to long acting injectable (LAI) risperidone
Mean age was 39.5 years (SD 11.8; range 37.5–41); majority
were male (mean 61%; range 56–70%). 98% had a diagnosis of
schizophrenia or schizoaffective disorder (range 98–100%).
Mean duration of illness was 10.8 years (SD 9.3; range 9.2–12.6
years). Majority of patients (>80%) at baseline had a CGI-S
score of 4–6 indicating that patients were moderately (35%),
markedly (34%) or severely (18%) ill. The GAF scores were
similar across countries (mean 46; SD 15; range 43–48). There
were country differences in hospitalisation history during the 12-
month retrospective period: 28%, 70%, and 17% of patients in
Germany, Spain and Australia respectively had no hospitalisa-
tions; for patients with hospitalisations, the mean number of
days hospitalised per patient was 58.2 (SD 53.1), 38.3 (SD 51.1),
and 66.9 (SD 90.3) respectively. Prior to the switch to (LAI)
risperidone, 67–90% patients were taking oral atypicals,
27–35% oral conventionals, and 22–52% depot conventionals.
The most frequent reason for switching was compliance:
Germany (37%), Australia (52%), Spain (30%). CONCLU-
SIONS: Compliance remains an important treatment issue even
for those treated with atypicals. Continued enrollment, and
follow-up will enable a better understanding of a broader range
of treatment patterns in schizophrenic patients
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OBJECTIVES: E-STAR is an international, non-interventional,
observational study of clinical and economic outcomes in schiz-
ophrenia/schizoaffective patients who switch to a new antipsy-
chotic. METHODS: Data over a 12-month retrospective and 24
month prospective period from in- or out-patients who start on
a new antipsychotic medication are collected via a secure,
privacy-protected web-site. All data are automatically checked
against validation rules at the point of entering the study. The
validation rules are established in consultation with specialists 
in data analysis and key opinion leaders, and are designed to
prevent missing data, duplicate data and data outside pre-
established, reasonable ranges. These require conﬁrmation by the
physician before the system will accept them. If data is entered
incorrectly, the physician submits correction requests via an
audited online data change request system. A further supple-
mental audit process is used to control quality of uploaded data.
This process uses monthly reports to identify potential inconsis-
tencies within the dataset after data has been validated at entry.
RESULTS: Uploaded data undergoing quality control checks,
requiring adjustment by physicians, is minimal. Audit reports
have helped redress data entry training issues, further enhancing
data accuracy. Analysis is only conducted on patients after res-
olution of outstanding supplemental data queries. Conclusion:
This largely automated three stage quality control process is
important to the implementation of non-interventional, obser-
vational research such as this, where the goal is to study out-
comes in a generalisable, representative patient cohort. This
permits the inclusion of patients from a broad geographic region,
which will add signiﬁcantly to our understanding of the use of
anti-psychotics in actual clinical practice, outside of the inﬂuence
of clinical trial settings. This also allows for much faster analy-
sis and presentation of robust, pragmatic outcomes data.
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OBJECTIVES: Compare patient- and caregiver-reported out-
comes on 25 objective questions contained within the 51-item
Schizophrenia Outcomes Assessment Project (SOAP) quality of
life survey. METHODS: In total, 1500 community-residing indi-
viduals with schizophrenia in ﬁve states (Massachusetts, South
Carolina, Wisconsin, Arizona, Washington) completed SOAP-51
survey at baseline and weeks four, ﬁve, and 12. Previously, factor
analysis indicated that SOAP-51 had eight factors (satisfaction,
self concept, work/role, mental health, interpersonal, medication
effects, activities of daily living, and physical function) with
Cronbach alphas ranging from 0.728–0.937 and test/retest intr-
aclass correlations >0.70 for all but one factor. An expert panel
identiﬁed 25 SOAP items that could be objectively measured.
This 25-item subset was given to each patient’s primary caregiver
concurrent with each patient’s SOAP-51 administration. Care-
givers were asked to answer each item in two ways: 1) What is
your objective response?; and 2) What do you think is the
patient’s response? Three correlation sets were performed for
week-four responses: a) caregiver’s objective responses compared
to caregiver’s estimation of patient’s responses (Correlation A);
b) caregiver’s objective response compared to patient’s responses
(Correlation B); and c) caregiver’s estimation of patient’s
responses compared to patient’s responses (Correlation C).
RESULTS: Strongest correlations occurred in Correlation A
[factor scores for caregiver’s objective responses compared to
caregiver’s estimation of patient’s responses (0.534–0.862)];
lowest for Correlation B [caregiver’s objective response com-
pared to patient’s responses (-0.292–0.367)]; and intermediate
for Correlation C [caregiver’s estimation of patient’s responses
compared to patient’s responses (-0.353–0.564)]. Physical func-
tion factor correlations were the strongest in Correlation A
(0.862), but the lowest in Correlation B (-0.292) and C (-0.353).
CONCLUSIONS: Caregiver objective assessments of indivi-
duals with schizophrenia can vary markedly from patient-
reported outcomes, but asking caregivers to view the world
through the eyes of the patient closes this gap. Asking caregivers
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to assume a patient’s perspective may improve patient-caregiver
communications.
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OBJECTIVE: To assess differences in the valuation of eight
schizophrenia-related health states using a multi-attribute utility
instrument (MAU)—the Assessment of Quality of Life Ques-
tionnaire (AQoL), and two scaling techniques: the time trade-off
(TTO) and a visual analogue scale (VAS). METHODS: Eight
schizophrenia-related health state scenarios based on severity of
symptoms were presented to 87 participants from the general
population. Scenarios were: A) “good” function with no move-
ment disorders [extrapyramidal symptoms]; B) “good” function
with movement disorders; C) “poor” function with no move-
ment disorders; D) “poor” function with movement disorders;
E) hospitalised relapse with no movement disorders; F) hospi-
talised relapse with movement disorders; G) post-hospitalisation
with no movement disorders; and H) post-hospitalisation with
movement disorders. Participants were educated about how the
symptoms described in these scenarios could impact on quality
of life and were then asked to value each health state using 
the AQoL, TTO, and a VAS ranging from 0–100. RESULTS:
Mean utility values for all health states ranged from 0.68 to 0.01,
0.80 to 0.53, and 0.74 to 0.17 for the AQoL, TTO and VAS,
respectively. For each instrument or scale there was a trend for
higher utility values to be associated with better outcomes and
lower utility values to be associated with poorer outcomes. 
There were differences between the global results for AQoL,
TTO and VAS [Kruskal-Wallis test (p < 0.001)] and differences
between the utility measures for each health state, except
between TTO and VAS results for health state A (p = 0.655),
and between the AQoL and VAS results for health state G (p =
0.094). CONCLUSION: Utility values varied across health states
and in most cases differed signiﬁcantly between instrument
and/or scale. For schizophrenia, the results from AQoL are most
sensitive to differing symptom severity. However, further
research comparing the different utility instruments is required
in this disease area.
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GREATER DEPRESSIVE SYMPTOMS ARE ASSOCIATED WITH
WORSE FUNCTIONAL OUTCOMES IN PATIENTS DIAGNOSED
WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER
Phillips GA,Ascher-Svanum H, Chen L, Kinon B
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OBJECTIVE: To assess the relationships between depressive
symptoms and functional outcomes in the treatment of patients
diagnosed with schizophrenia or schizoaffective disorder.
METHODS: This was a post-hoc analysis of a randomized,
double-blind, 24-week study of antipsychotic treatment for
patients diagnosed with schizophrenia or schizoaffective disor-
ders with prominent depressive symptoms (N = 394). Measures
included the SCAP Health Questionnaire (SCAP-HQ) for func-
tional outcomes and the Montgomery-Åsberg Depression Rating
Scale (MADRS) for depressive symptoms. Associations between
depressive symptoms at baseline and functional outcomes at
baseline and at 24-weeks (LOCF) were evaluated controlling for
severity of schizophrenia symptoms (measured with the Positive
and Negative Symptoms Scale (PANSS)) and extrapyramidal
symptoms measured with the Barnes Akathisia Scale, the
Simpson-Angus Scales, and the Abnormal Involuntary Move-
ment Scale (AIMS). RESULTS: At baseline, depressive symptoms
were signiﬁcantly correlated with baseline PANSS Positive Symp-
toms and General Psychopathology (p < 0.001), but not with
Negative Symptoms. At baseline, greater severity of depressive
symptoms signiﬁcantly correlated with a higher likelihood of
baseline violent behaviors, suicidal ideations, suicide attempts,
and substance use; and a decreased likelihood of baseline 
participation in a day treatment program and common leisure 
activities (all p < 0.050). Baseline severity of depressive symp-
toms was signiﬁcantly associated with poorer mental health
functioning, increased likelihood of suicidal ideations and sub-
stance use, and with decreased likelihood of participation in a
day treatment program at endpoint (all p < 0.050). CONCLU-
SIONS: Depressive symptoms in schizophrenia or schizoaffective
disorder are associated with worse functional outcomes, both
concurrently and after 24-weeks of treatment with antipsychotic
medications.
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OBJECTIVES: Prior to use in an international study involving
children and adolescents suffering from schizophrenia or bipolar
disorders, the original 21-item Caregiver Strain Questionnaire
(CGSQ) underwent linguistic validation in 19 languages. The
original scale, which measures the strain of caring for children
with emotional and/or behavioural problems on their caregivers,
was developed in US English. A rigorous methodology was
required to ensure conceptual equivalence and cultural relevance
across different languages. METHODS: The translation process
was conducted by a specialist in each target country using the
following standardized methodology: 1) two forward transla-
tions by professional translators who were native speakers of the
target language and ﬂuent in English; 2) comparison and recon-
ciliation of the translations by the specialist in the target country
and the translators; 3) backward translation by a native English
speaker; 4) comparison of source and backward version; 5)
review by a clinician; and 6) comprehension test on ﬁve parents
of children suffering from schizophrenia or bipolar disorders.
RESULTS: The translation process revealed two types of chal-
lenges: a) the translation of technical terms and b) the transla-
tion of idiomatic expressions. In the ﬁrst case the expression
“negative mental and physical health effects” required a simpli-
ﬁed description in the translations. Similarly, the term “care-
giver”, having no literal equivalent, had to be replaced by the
mention of the actual person providing care. As for translations
of idiomatic expressions, paraphrases were often needed to
convey the intended meaning. CONCLUSIONS: The 19 lan-
guage versions of the CGSQ were established according to a rig-
orous translation methodology. The process aims to ensure
conceptual equivalence across different language versions to
facilitate international comparison and pooling of data. The lin-
guistic validation process as a whole supports the advantage of
integrating international feedback on concepts and wording
before a questionnaire is ﬁnalized.
